The Use of Nicotinamide as a Treatment for Experimental Traumatic Brain Injury and Stroke: A Review and Evaluation
|Cole Vonder Haar, Todd C Peterson, Kris M Martens and Michael R Hoane*|
|Restorative Neuroscience Laboratory, Center for Integrated Research in Cognitive and Neural Sciences, Department of Psychology, Southern Illinois University, Carbondale, IL, USA|
|Corresponding Author :||Hoane MR, Ph.D.
Restorative Neuroscience Laboratory
Department of Psychology, Life Science II
MC 6502, Southern Illinois University
Carbondale, IL, 62901, USA
E-mail: [email protected]
|Received February 07, 2013; Accepted March 25, 2013; Published March 30, 2013|
|Citation: Haar CV, Peterson TC, Martens KM, Hoane MR (2013) The Use of Nicotinamide as a Treatment for Experimental Traumatic Brain Injury and Stroke: A Review and Evaluation. Clin Pharmacol Biopharm S1:005. doi:10.4172/2167-065X.S1-005|
|Copyright: © 2013 Haar CV, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Traumatic Brain Injury (TBI) and stroke are leading causes of neurological dysfunction and are major health concerns worldwide. Much research has been conducted on the processes at work in TBI and stroke; however, to date no pharmaceutical treatments have been shown to be effective in treating human clinical TBI and only one drug has been approved for human stroke treatment. Thus, many laboratories have begun to investigate organic compounds such as vitamins and other nutrients. Specifically, nicotinamide (vitamin B3) has been studied in the laboratory to assess its effectiveness as a treatment following TBI or stroke. This review evaluates the experimental evidence for the use of nicotinamide to treat brain injury. Based on the evidence from animal models, there is considerable potential for the use of nicotinamide to treat TBI and stroke. However there are still some factors that need to be further investigated before considering clinical trials.